Intravenous versus subcutaneous dosing of Epoetin alfa in hemodialysis patients
Open Access
- 1 August 1995
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 26 (2) , 331-340
- https://doi.org/10.1016/0272-6386(95)90654-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Intravenous Versus Subcutaneous Dosing of Epoetin: A Review of the LiteratureAmerican Journal of Kidney Diseases, 1993
- Subcutaneous Recombinant Human Erythropoietin in Hemodialysis and Continuous Ambulatory Peritoneal DialysisPeritoneal Dialysis International, 1993
- Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal diseaseJournal of the American Society of Nephrology, 1992
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989
- Epoetin (Recombinant Human Erythropoietin)Drugs, 1989
- PHARMACOKINETICS OF RECOMBINANT HUMAN ERYTHROPOIETIN IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSISThe Lancet, 1989
- Single-dose Pharmacokinetics of Recombinant Human Erythropoietin in Patients with Various Degrees of Renal FailureNephrology Dialysis Transplantation, 1989
- Correction of the Anaemia of Chronic Renal Failure with Erythropoietin: Pharmacokinetic Studies in Patients on Haemodialysis and CAPDPublished by S. Karger AG ,1989
- Pharmacokinetics of Recombinant Human Erythropoietin after SC Administration and in Long-Term IV Treatment in Patients on Maintenance HemodialysisPublished by S. Karger AG ,1988